Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expected to Post Quarterly Sales of $58.03 Million

Share on StockTwits

Equities research analysts predict that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will announce sales of $58.03 million for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $56.40 million to $60.00 million. Vanda Pharmaceuticals reported sales of $49.14 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.1%. The company is scheduled to report its next earnings report on Wednesday, November 6th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full-year sales of $224.33 million for the current fiscal year, with estimates ranging from $220.10 million to $229.00 million. For the next financial year, analysts expect that the company will post sales of $274.63 million, with estimates ranging from $247.10 million to $326.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.24. Vanda Pharmaceuticals had a return on equity of 10.23% and a net margin of 13.61%. The business had revenue of $59.06 million during the quarter, compared to the consensus estimate of $54.19 million. During the same period last year, the company earned $0.15 EPS. The company’s revenue for the quarter was up 24.7% on a year-over-year basis.

A number of research firms have recently weighed in on VNDA. Citigroup upgraded Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a report on Thursday, August 1st. Oppenheimer set a $18.00 price target on Vanda Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, May 5th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Friday, August 2nd. ValuEngine upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $17.00 price target on shares of Vanda Pharmaceuticals in a report on Wednesday, July 31st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $26.57.

In related news, CEO Mihael Hristos Polymeropoulos sold 72,872 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $15.34, for a total transaction of $1,117,856.48. Following the completion of the transaction, the chief executive officer now directly owns 1,276,343 shares in the company, valued at approximately $19,579,101.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Timothy Williams sold 2,575 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total value of $37,826.75. Following the transaction, the senior vice president now owns 57,425 shares of the company’s stock, valued at $843,573.25. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Comerica Bank boosted its holdings in Vanda Pharmaceuticals by 1.4% during the 1st quarter. Comerica Bank now owns 51,842 shares of the biopharmaceutical company’s stock valued at $928,000 after acquiring an additional 725 shares during the period. Piedmont Investment Advisors Inc. boosted its holdings in Vanda Pharmaceuticals by 5.9% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 13,198 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 737 shares during the period. United Services Automobile Association boosted its holdings in Vanda Pharmaceuticals by 5.8% during the 2nd quarter. United Services Automobile Association now owns 14,544 shares of the biopharmaceutical company’s stock valued at $205,000 after acquiring an additional 792 shares during the period. Rhumbline Advisers boosted its holdings in Vanda Pharmaceuticals by 0.6% during the 1st quarter. Rhumbline Advisers now owns 149,949 shares of the biopharmaceutical company’s stock valued at $2,759,000 after acquiring an additional 832 shares during the period. Finally, Arizona State Retirement System boosted its holdings in Vanda Pharmaceuticals by 1.2% during the 2nd quarter. Arizona State Retirement System now owns 82,158 shares of the biopharmaceutical company’s stock valued at $1,158,000 after acquiring an additional 949 shares during the period. Institutional investors own 99.33% of the company’s stock.

Shares of VNDA traded up $0.28 during midday trading on Tuesday, reaching $15.19. The company had a trading volume of 525,000 shares, compared to its average volume of 893,224. Vanda Pharmaceuticals has a 1-year low of $11.83 and a 1-year high of $33.44. The stock has a market cap of $794.31 million, a PE ratio of 31.65 and a beta of 0.38. The firm has a 50 day simple moving average of $13.91 and a 200-day simple moving average of $16.65.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: American Cannabis Company, Inc  Major Shareholder Sells $31,066.65 in Stock
Insider Selling: American Cannabis Company, Inc Major Shareholder Sells $31,066.65 in Stock
Eaton Vance New York Municipal Bond Fund Plans — Dividend of $0.04
Eaton Vance New York Municipal Bond Fund Plans — Dividend of $0.04
StoneCastle Financial Corp  Plans Quarterly Dividend of $0.38
StoneCastle Financial Corp Plans Quarterly Dividend of $0.38
KLA-Tencor  Updates Q1 2020 Earnings Guidance
KLA-Tencor Updates Q1 2020 Earnings Guidance
Federal Realty Investment Trust  Announces Quarterly Dividend of $1.05
Federal Realty Investment Trust Announces Quarterly Dividend of $1.05
Anthem  Releases FY 2019 Earnings Guidance
Anthem Releases FY 2019 Earnings Guidance


 
© 2006-2019 Zolmax.